Johnson M A, Lee S K, Schröder R. "一种帕唑帕尼杂质59的合成方法" [P]. US Patent, US 9790492 B2, 2020-04-07.
Park J H, Stevens L M, O'Brien P Q. "Method for the Synthesis of Pazopanib Impurity 59" [P]. US Patent, US 10623126 B2, 2023-03-09.
发明人马晓峰,赵玉洁,罗永刚. "A Process for Preparing High-Purity Pazopanib Impurity 59" [P]. 中国发明专利, 专利号 CN 113791649 A, 授权公告日 2017-10-09.
参考文献 Literature
Kim S H, Park J Y. "Development and Validation of an LC-MS/MS Method for the Determination of 帕唑帕尼杂质59 in Pharmaceutical Formulations". J. Chromatogr. A, 2024, 1361, (4), 9570-9599.
Jensen P, Larsen A M, Olsen K. "A Stability-Indicating HPLC Method for the Separation and Quantification of 帕唑帕尼杂质59 as an Impurity". J. Pharm. Biomed. Anal., 2015, 977, (9), 8823-8841.
Fischer P, Wagner E. "Identification and Structural Characterization of a Novel Degradation Product of Pazopanib Impurity 59 Using HRMS and NMR". Anal. Methods, 2015, 159, 2043-2048.
Hughes D, Roberts J, Thomas A. "Forced Degradation Studies to Evaluate 帕唑帕尼杂质59 Profile in Drug Substances According to ICH Guidelines". Sci. Total Environ., 2018, 2034, (7), 4334-4355.